Literature DB >> 18184139

"Ecologic niche" therapy for Crohn's disease with adjunctive rifaximin antibiotic treatment followed by Flora-Q probiotic maintenance therapy.

David B Doman, Howard J Goldberg, Martin I Golding.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18184139     DOI： 10.1111/j.1572-0241.2007.01562_13.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  5 in total

Review 1.  Probiotics in pediatric inflammatory bowel diseases.

Authors:  Ajay S Gulati; Marla C Dubinsky
Journal:  Curr Gastroenterol Rep       Date:  2009-06

2.  Campylobacter concisus: a new character in the Crohn's disease story?

Authors:  Mario Guslandi; Li Zhang; Si Ming Man; Andrew S Day; Steven T Leach; Daniel A Lemberg; Shoma Dutt; Michael Stormon; Anthony Otley; Edward V O'Loughlin; Annabel Magoffin; Patrick H Y Ng; Hazel Mitchell
Journal:  J Clin Microbiol       Date:  2009-05       Impact factor: 5.948

3.  Rifaximin and Crohn's disease: a new solution to an old problem?

Authors:  A S Day; R B Gearry
Journal:  Dig Dis Sci       Date:  2010-04       Impact factor: 3.199

4.  The emerging therapeutic role of probiotics in inflammatory bowel disease.

Authors:  Matthew Chandler; Eric Wollins; Anastasia Toles; Marie Borum; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-09

Review 5.  Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients.

Authors:  Daisy Jonkers; John Penders; Ad Masclee; Marieke Pierik
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.